Want to join the conversation?
$CELG 2Q15 Call: REVLIMID's growth accelerated significantly in Q2 and quarterly revenue surpassed $1.44Bil. Excluding the negative impact of Forex, REVLIMID’s year-over-year growth in Q2 was 21% & was mainly volume driven & the favorable impact of US price increases is largely being offset by price declines in Europe.
$RAI has received a $47 billion take over offer from British tobacco giant British American Tobacco! This is huge!
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.